Oxycodone vs Levorphanol — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Opioid Agonist

Oxycodone

Brand: OXAYDO

First FDA approval: 2000-08-31

Opioid Agonist

Levorphanol

First FDA approval: 2000-03-31

Lowest NADACAcquisition cost floor across all NDCs

$0.045Per unit

$10.65Per unit

Average NADACAcross all dosage forms and strengths

$2.87Up to $32.73

$10.65Up to $10.65

Generic manufacturersActive ANDA holders — FDA Orange Book

1867 total ANDAs filed

58 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$737.4MFull year

$20.6MFull year

Part D claims (CY24)Total fills, all strengths

14.7M4.7M beneficiaries

7K1K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$50Per claim, all NDCs

$3,020Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

254Substantial friction

2Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes18 manufacturers

Yes5 manufacturers